Physician profile
Erryn Tappy
NPI 1720442106
$4,556.30
in general payments reported to CMS, 2019-2025
22 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,234 · 2024: $679 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916 · Travel and Lodging: $1,640 · Education: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.90 |
| Travel and Lodging | $1,640.40 |
| Education | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,836.04 | 2023 | Axonics, Bulkamid |
| Intuitive Surgical, INC. | $1,028.98 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $276.86 | 2023-2025 | Botox |
| Sumitomo Pharma America, INC. | $243.25 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $241.61 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Coloplast Corp | $165.46 | 2023-2025 | Restorelle, Altis |
| Janssen Biotech, INC. | $138.76 | 2024-2025 | Erleada, Akeega, Balversa |
| Boston Scientific Corporation | $124.35 | 2023-2025 | Axonics, Upsylon |
| Urogen Pharma, INC. | $108.47 | 2023-2024 | Jelmyto |
| Bluewind Medical | $69.37 | 2024 | Revi |
| Astellas Pharma US INC | $53.49 | 2025 | Xtandi, Padcev |
| Pfizer INC. | $37.05 | 2024-2025 | |
| Teleflex LLC | $34.40 | 2024 | Quikclot |
| Immunitybio, INC. | $33.75 | 2024-2025 | |
| Convatec INC. | $29.77 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Progenics Pharmaceuticals, INC. | $22.61 | 2025 | |
| Blue Earth Diagnostics | $21.47 | 2024 | |
| Ferring Pharmaceuticals INC. | $19.02 | 2025 | Adstiladrin |
| Verity Pharmaceuticals INC. | $18.63 | 2025 | Trelstar |
| Laborie Medical Technologies Corp. | $14.02 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2023 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erryn Tappy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.